Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Plasma cell 1Gynecologic 1Breast 1

Conditions

Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Tongue Neoplasms 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Osteosarcoma 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × saracatinib × Clear all
NCT00265876 2023-08-04

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Canadian Cancer Trials Group

Phase 1/2 Completed
34 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00735917 2019-04-02

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡